A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2019
Price : $35 *
At a glance
- Drugs Pimavanserin (Primary)
- Indications Aggression; Agitation
- Focus Adverse reactions
- Sponsors Acadia Pharmaceuticals
- 11 Apr 2019 Status changed from active, no longer recruiting to completed.
- 19 Mar 2019 Planned number of patients changed from 111 to 432.
- 28 Feb 2018 Planned number of patients changed from 432 to 111.